Dagon Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 Cr
as on 23-10-2024
- Paid Up Capital ₹ 2.25 Cr
as on 23-10-2024
- Company Age 31 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 17.06 Cr
as on 23-10-2024
- Satisfied Charges ₹ 4.45 Cr
as on 23-10-2024
- Revenue -19.36%
(FY 2023)
- Profit 7.65%
(FY 2023)
- Ebitda -25.24%
(FY 2023)
- Net Worth 10.43%
(FY 2023)
- Total Assets 13.18%
(FY 2023)
About Dagon Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 Cr and a paid-up capital of Rs 2.25 Cr.
The company currently has active open charges totaling ₹17.06 Cr. The company has closed loans amounting to ₹4.45 Cr, as per Ministry of Corporate Affairs (MCA) records.
Kishorbhai Bhut, Bhupatbhai Bhut, and Gautam Bhut serve as directors at the Company.
- CIN/LLPIN
U24231GJ1993PTC019247
- Company No.
019247
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Apr 1993
- Date of AGM
17 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Dagon Pharmaceuticals Private Limited offer?
Dagon Pharmaceuticals Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Mineral Supplement, Vitamin Tablets & Capsules, Digestive System Drugs & Medicines, Antacid Drugs, Pharma Franchise, PCD Pharma Franchise, Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup, Pain Relief Drugs & Pharmaceuticals.
Who are the key members and board of directors at Dagon Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kishorbhai Bhut  | Whole-Time Director | 02-Apr-1993 | Current |
| Bhupatbhai Bhut | Director | 02-Feb-2005 | Current |
| Gautam Bhut | Whole-Time Director | 24-Mar-2001 | Current |
Financial Performance of Dagon Pharmaceuticals.
Dagon Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 19.36% decrease. The company also saw a slight improvement in profitability, with a 7.65% increase in profit. The company's net worth Soared by an impressive increase of 10.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dagon Pharmaceuticals?
In 2023, Dagon Pharmaceuticals had a public holding of 23.79%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sidbi Creation Date: 26 Jul 2024 | ₹1.12 Cr | Open |
Sidbi Creation Date: 26 Jul 2024 | ₹9.30 M | Open |
Sidbi Creation Date: 02 Mar 2022 | ₹1.23 Cr | Open |
How Many Employees Work at Dagon Pharmaceuticals?
Unlock and access historical data on people associated with Dagon Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dagon Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dagon Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
